Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vaccines

Showing results (681-690 of 10,021) with videos related to

Pageof 1,003
Sort By:
Vaccines|December 3, 2020
Type IIb Heat Labile Enterotoxin B Subunit as a Mucosal Adjuvant to Enhance Protective Immunity against H5N1 Avian Influenza VirusesNeos Tang, Chun-Yi Lu, Shih-Che Sue, et al.
Vaccines|December 4, 2020
Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control AssayThomas J M Michiels, Wichard Tilstra, Martin R J Hamzink, et al.
Vaccines|December 5, 2020
Redefining Non-Inferiority in Anamnestic Antibody Responses Using the Mean Increase of Log-Transformed Antibody Titers after Revaccination: Secondary Analysis of a Randomized Controlled Rabies Vaccination TrialLisanne A Overduin, Patrick H P Soentjens, Jelle J Goeman, et al.
Vaccines|December 5, 2020
Standardized Methodology for Target Surveillance against African Swine FeverStefano Cappai, Sandro Rolesu, Francesco Feliziani, et al.
Vaccines|December 5, 2020
Nanoparticles (PLGA and Chitosan)-Entrapped ADP-Ribosylation Factor 1 of <i>Haemonchus contortus</i> Enhances the Immune Responses in ICR MiceMuhammad Waqqas Hasan, Muhammad Haseeb, Muhammad Ehsan, et al.
Vaccines|December 5, 2020
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic TreatmentsPaolo Gisondi, Francesco Bellinato, Andrea Chiricozzi, et al.
Vaccines|October 31, 2020
Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?Jeroen Luyten, Roselinde Kessels, Corinne Vandermeulen, et al.
Vaccines|December 9, 2020
Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)Paulina N Naupu, Albertha R van Zyl, Edward P Rybicki, et al.
Vaccines|December 9, 2020
DNA Vaccine Development at Pre- and Post-Operation Warp SpeedKarl Ljungberg, Maria Isaguliants
Vaccines|December 10, 2020
Serum Anti-HPV Antibody Titer as a Marker of Vaccine Effectiveness in Males with Genital InfectionLuca De Toni, Francesco Muscianisi, Christian Corsini, et al.
Pageof 1,003

Showing results (681-690 of 10,021) with videos related to

Sort By:
Pageof 1,003
Vaccines|December 3, 2020
Type IIb Heat Labile Enterotoxin B Subunit as a Mucosal Adjuvant to Enhance Protective Immunity against H5N1 Avian Influenza VirusesNeos Tang, Chun-Yi Lu, Shih-Che Sue, et al.
Vaccines|December 4, 2020
Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control AssayThomas J M Michiels, Wichard Tilstra, Martin R J Hamzink, et al.
Vaccines|December 5, 2020
Redefining Non-Inferiority in Anamnestic Antibody Responses Using the Mean Increase of Log-Transformed Antibody Titers after Revaccination: Secondary Analysis of a Randomized Controlled Rabies Vaccination TrialLisanne A Overduin, Patrick H P Soentjens, Jelle J Goeman, et al.
Vaccines|December 5, 2020
Standardized Methodology for Target Surveillance against African Swine FeverStefano Cappai, Sandro Rolesu, Francesco Feliziani, et al.
Vaccines|December 5, 2020
Nanoparticles (PLGA and Chitosan)-Entrapped ADP-Ribosylation Factor 1 of <i>Haemonchus contortus</i> Enhances the Immune Responses in ICR MiceMuhammad Waqqas Hasan, Muhammad Haseeb, Muhammad Ehsan, et al.
Vaccines|December 5, 2020
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic TreatmentsPaolo Gisondi, Francesco Bellinato, Andrea Chiricozzi, et al.
Vaccines|October 31, 2020
Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?Jeroen Luyten, Roselinde Kessels, Corinne Vandermeulen, et al.
Vaccines|December 9, 2020
Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)Paulina N Naupu, Albertha R van Zyl, Edward P Rybicki, et al.
Vaccines|December 9, 2020
DNA Vaccine Development at Pre- and Post-Operation Warp SpeedKarl Ljungberg, Maria Isaguliants
Vaccines|December 10, 2020
Serum Anti-HPV Antibody Titer as a Marker of Vaccine Effectiveness in Males with Genital InfectionLuca De Toni, Francesco Muscianisi, Christian Corsini, et al.
Pageof 1,003